Welcome to LookChem.com Sign In|Join Free
  • or
3-(4,5-dimethoxy-2-nitrophenyl)propan-1-ol is a chemical with a specific purpose. Lookchem provides you with multiple data and supplier information of this chemical.

20716-22-7

Post Buying Request

20716-22-7 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

20716-22-7 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 20716-22-7 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 2,0,7,1 and 6 respectively; the second part has 2 digits, 2 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 20716-22:
(7*2)+(6*0)+(5*7)+(4*1)+(3*6)+(2*2)+(1*2)=77
77 % 10 = 7
So 20716-22-7 is a valid CAS Registry Number.

20716-22-7Downstream Products

20716-22-7Relevant academic research and scientific papers

Process for Synthesis of Chiral 3-Substituted Tetrahydroquinoline Derivatives

-

Paragraph 0044; 0059; 0060, (2015/02/19)

The present invention relates to novel and concise process for the construction of chiral 3-substituted tetrahyroquinoline derivatives based on proline catalyzed asymmetric α-functionalization of aldehyde, followed by in situ reductive cyclization of nitro group under catalytic hydrogenation condition with high optical purities. Further the invention relates to conversion of derived chiral 3-substituted tetrahydroquinoline derivatives into therapeutic agents namely (?)-sumanirole (96% ee) and 1-[(S)-3-(di-methylamino)-3,4-dihydro-6,7-dimethoxy-quinolin-1(2H)-yl]propanone[(S)-903] (92% ee).

A PROCESS FOR SYNTHESIS OF CHIRAL 3-SUBSTITUTED TETRAHYDROQUINOLINE DERIVATIVES

-

Page/Page column 22, (2013/10/08)

The present invention relates to novel and concise process for the construction of chiral 3-substituted tetrahydroquinoline derivatives based on proline catalyzed asymmetric α-functionalization of aldehyde, followed by in situ reductive cyclization of nitro group under catalytic hydrogenation condition with high optical purities. Further the invention relates to conversion of derived chiral 3-substituted tetrahydroquinoline derivatives into therapeutic agents namely (-)-sumanirole (96% ee) and 1-[(S)-3-(dimethylamino)-3,4-dihydro-6,7-dimethoxy-quinolin-1(2H)-yl]propanone[(S)-903] (92% ee).

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 20716-22-7